Réka Shinkle, MBAVice President, Commercial and Portfolio Planning at REGENXBIO
Réka Shinkle joined REGENXBIO as the Vice President, Commercial and Portfolio Planning in April 2015. Previously, Ms. Shinkle held increasing commercial responsibility spanning small molecule and biologic products in multiple therapeutic areas at Lilly, MedImmune, and AstraZeneca. Ms. Shinkle’s current responsibilities include building the commercial function at REGENXBIO while ensuring development of insight-driven gene therapy portfolio and product strategies with line of sight to commercialization. Ms. Shinkle earned her Masters in Business Administration cum laude from the University of Michigan.